AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

The FDA has granted approval for Celltrion's Avtozma in both IV and SC formulations as Actemra biosimilar for treating ...

Sanofi has received China’s NMPA approval for the use of Sarclisa, combined with a standard-of-care regimen, for treating ...

The EC has authorised the use of ViiV Healthcare’s Vocabria plus Rekambys from J&J for treating adolescents with HIV-1.

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

CDMO Rentschler Biopharma is signalling its intent to cut down cell and gene therapy operations by shutting down its UK ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

On 1 January 2025, important legal amendments relating to drug pricing in Germany included in the Medical Research Act came ...

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...